Cannabis,
Journal Year:
2022,
Volume and Issue:
5(2), P. 16 - 27
Published: July 11, 2022
Psychedelic-assisted
psychotherapy
has
established
antidepressant
effects.
Cannabis
users
appear
to
expect
high
doses
administered
in
a
session
much
like
psychedelic-assisted
create
comparable
subjective
The
current
studies
explored
expectations
of
effects
such
cannabis-assisted
sessions
replicate
and
extend
previous
work.
Users
not
only
expected
decrease
depression,
but
also
alter
some
the
same
mediators
psychedelic
or
psychological
treatments.
Over
500
participants
Study
I
envisioned
therapy
akin
those
used
therapies
reported
that
they
on
depression
as
well
relevant
reactions.
A
second
sample
over
responded
identical
measures
an
index
dysfunctional
attitudes
appears
mediate
psychotherapy.
Expectancies
cannabis-induced
covaried
with
Participants
would
attitudes,
which
served
separate,
unique
path
unrelated
psychedelics.
These
results
add
support
arguments
for
clinical
trials
suggest
cannabis
it
work
ways
similar
psychedelics
cognitive
therapy.
Journal of Clinical Medicine,
Journal Year:
2020,
Volume and Issue:
10(1), P. 15 - 15
Published: Dec. 23, 2020
Background:
The
landscape
of
attitudes,
legal
status
and
patterns
use
cannabis
is
rapidly
changing
in
the
United
States
elsewhere.
Therefore,
primary
aim
this
narrative
review
to
provide
a
concise
overview
literature
on
comorbidity
disorder
(CUD)
with
other
substance
psychiatric
disorders,
information
accurately
guide
future
directions
for
field.
Methods:
A
PubMed
was
conducted
studies
relating
use,
CUD,
co-occurring
disorder.
To
an
representative
data,
focused
national-level,
population-based
work
from
National
Epidemiologic
Survey
Alcohol
Related
Conditions
(NESARC)
Drug
Use
Health
(NSDUH)
surveys.
Considering
laws,
recent
(past
five-year)
were
addressed.
Results:
strong
body
shows
associations
between
CUD
drug
psychosis,
mood
anxiety
personality
disorders.
strongest
evidence
potential
causal
relationship
exists
psychotic
While
some
directionality
results
are
inconsistent.
Studies
have
established
higher
rates
among
those
but
little
about
specifics
understood.
Conclusions:
Although
general
population
increasingly
perceives
be
harmless
substance,
empirical
that
associated
both
comorbid
illness.
However,
there
mixed
regarding
role
etiology,
course,
prognosis
across
all
categories
Future
research
should
expand
existing
representative,
longitudinal
order
better
understand
acute
long-term
effects
JAMA Network Open,
Journal Year:
2021,
Volume and Issue:
4(6), P. e2113025 - e2113025
Published: June 22, 2021
Importance
During
the
past
decade,
cannabis
use
among
US
adults
has
increased
markedly,
with
a
parallel
increase
in
suicidality
(ideation,
plan,
attempt,
and
death).
However,
associations
between
young
are
poorly
understood.
Objective
To
determine
whether
disorder
(CUD)
associated
higher
prevalence
of
or
without
depression
to
assess
these
vary
by
sex.
Design,
Setting,
Participants
This
survey
study
examined
data
from
281
650
aged
18
34
years
who
participated
National
Surveys
on
Drug
Use
Health.
Data
were
collected
January
1,
2008,
December
31,
2019.
Exposures
Prevalence
past-year
daily
near-daily
(≥300
days
year),
CUD,
major
depressive
episode
(MDE).
Past-year
CUD
MDE
based
onDSM-IVdiagnostic
criteria.
Main
Outcomes
Measures
suicidal
ideation,
attempt.
Results
Among
(men,
49.9%
[95%
CI,
49.6%-50.2%];
women,
50.1%
49.8%-50.4%])
included
analysis,
ideation
plan
along
all
sociodemographic
subgroups
(except
current
high-school
students),
suicide
attempt
most
subgroups.
trends
adjusted
varied
nondaily
MDE.
After
controlling
for
MDE,
status,
potential
confounding
factors,
1.4
1.6
times
2008-2009
2018-2019
periods
(adjusted
risk
ratio
[ARR]
1.3-1.5];
ARR
1.5-1.9];
1.2-1.7]),
2008
2009
as
reference
period.
use,
both
sexes
(eg,
individuals
those
vs
was
13.9%
3.5%
women
9.9%
3.0%
men;P<
.001),
but
significantly
more
so
than
men
52%
[23.7%]
[15.6%];P
<
.001).
Conclusions
Relevance
From
2019,
40%
60%
over
increases
ascribed
Future
research
is
needed
examine
this
it
due
overlapping
factors.
JAMA Network Open,
Journal Year:
2023,
Volume and Issue:
6(5), P. e2311294 - e2311294
Published: May 3, 2023
Importance
Cannabis
use
is
increasingly
viewed
by
adolescents
as
not
harmful.
Youths
with
cannabis
disorder
(CUD)
are
recognized
clinicians
being
at
risk
for
adverse
outcomes,
yet
little
known
about
the
associations
between
subclinical
(ie,
nondisordered
[NDCU])
and
psychosocial
events.
Objective
To
describe
prevalence
demographics
of
NDCU
to
compare
events
among
no
use,
NDCU,
CUD.
Design,
Setting,
Participants
This
cross-sectional
study
used
a
nationally
representative
sample
derived
from
2015
2019
National
Survey
on
Drug
Use
Health.
were
aged
12
17
years,
separated
into
3
distinct
groups:
nonuse
(no
recent
use),
(recent
below
diagnostic
threshold),
Analysis
was
conducted
January
May
2022.
Exposures
CUD,
or
nonuse.
defined
endorsing
but
meeting
Diagnostic
Statistical
Manual
Mental
Disorders
(
Fifth
Edition
)
DSM-5
CUD
criteria.
using
Main
Outcomes
Measures
The
main
outcomes
criteria
adjusted
sociodemographic
characteristics.
Results
68
263
respondents
(mean
[SD]
age,
14.5
[1.7]
years;
34
773
[50.9%]
males)
included
in
analysis
represented
an
estimated
yearly
mean
25
million
US
during
2019.
Among
respondents,
1675
(2.5%)
had
6971
(10.2%)
59
617
(87.3%)
reported
Compared
nonusers,
individuals
approximately
2
4
times
greater
odds
all
examined,
including
major
depression
(adjusted
ratio
[aOR],
1.86;
95%
CI,
1.67-2.08),
suicidal
ideation
(aOR,
2.08;
1.88-2.29),
slower
thoughts
1.76;
1.58-1.96),
difficulty
concentrating
1.81;
1.65-2.00),
truancy
1.90;
1.67-2.16),
low
grade
point
average
1.80;
1.62-2.00),
arrest
4.15;
3.17-5.43),
fighting
2.04;
1.80-2.31),
aggression
2.16;
1.79-2.62).
Prevalence
greatest
(range,
12.6%
41.9%),
followed
5.2%
30.4%),
then
0.8%
17.3%).
Conclusions
Relevance
In
this
adolescents,
past-year
prevalent
A
stepwise
gradient
association
observed
adolescent
context
normalization
prospective
research
necessary.
Frontiers in Public Health,
Journal Year:
2024,
Volume and Issue:
12
Published: April 9, 2024
Background
Problematic
cannabis
use
is
highly
prevalent
among
people
with
mood
disorders.
This
underscores
the
need
to
understand
effects
of
and
cannabinoids
in
this
population,
especially
considering
legalization
recreational
use.
Objectives
We
aimed
(1)
systematically
evaluate
cross-sectional
longitudinal
studies
investigating
interplay
between
use,
disorder
(CUD),
occurrence
disorders
symptoms,
a
focus
on
major
depressive
(MDD)
bipolar
(BD)
and;
(2)
examine
prognosis
treatment
outcomes
MDD
BD.
Methods
Following
PRISMA
guidelines,
we
conducted
an
extensive
search
for
English-language
potential
impact
development
published
from
inception
through
November
2023,
using
EMBASE,
PsycINFO,
PubMed,
MEDLINE
databases.
Results
Our
literature
identified
3,262
studies,
78
meeting
inclusion
criteria.
found
that
associated
increased
manic
symptoms
general
population
addition
elevated
likelihood
developing
Furthermore,
observed
linked
unfavorable
both
or
Discussion
findings
suggest
may
negatively
influence
development,
course,
Future
well-designed
type,
amount,
frequency
while
addressing
confounding
factors,
are
imperative
comprehensive
understanding
relationship.
Systematic
review
registration
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023481634
.
Frontiers in Public Health,
Journal Year:
2024,
Volume and Issue:
11
Published: Jan. 5, 2024
Background
There
are
well-established
literatures
documenting
the
associations
between
mental
disorders
and
unhealthy
behaviors
such
as
poor
diet
quality,
sedentary
behavior,
cannabis
tobacco
use.
Few
studies
have
attempted
to
understand
respective
findings
in
light
of
each
other,
however.
Objective
The
purpose
this
review
was
assemble
comparable
data
for
behavior-disorder
association
assess
terms
their
overall
strength.
aimed
include
a
representative,
but
not
exhaustive,
range
that
would
allow
explorative
comparisons.
Methods
Eligible
were
identified
via
Pubmed
searches
citation
searching,
restricted
publications
no
older
than
2015
written
English.
To
obtain
data,
only
reported
odds
ratios
included,
risk
bias
related
study
samples,
behavioral
measurement
disparities,
control
variables
assessed
sensitivity
analyses.
Findings
disorder
compared
on
basis
different
measures
central
tendency.
Results
From
3,682
records,
294
included.
found
evidence
four
psychosis,
depression,
anxiety,
bipolar
disorder,
attention-deficit/hyperactivity
(ADHD),
post-traumatic
stress
(PTSD),
while
personality
investigated
relation
In
comparison,
generally
similar
strength,
use
exceptional
being
significantly
stronger
its
counterparts
across
behaviors.
Analyses
some
influence
from
disparities
lack
adequate
statistical
control,
robust
Conclusion
This
comparative
about
equally
strongly
associated
with
disorders.
Given
general
nature
these
associations,
we
should
probably
them
reflect
shared
etiology.
However,
be
regarded
tentative
until
confirmed
by
more
comprehensive
investigations.
PLoS ONE,
Journal Year:
2023,
Volume and Issue:
18(9), P. e0289058 - e0289058
Published: Sept. 13, 2023
Background
Little
is
known
about
whether
people
who
use
both
tobacco
and
cannabis
(co-use)
are
more
or
less
likely
to
have
mental
health
disorders
than
single
substance
users
non-users.
We
aimed
examine
associations
between
of
and/or
with
anxiety
depression.
Methods
analyzed
data
from
the
COVID-19
Citizen
Science
Study,
a
digital
cohort
study,
collected
via
online
surveys
during
2020–2022
convenience
sample
53,843
US
adults
(≥
18
years
old)
nationwide.
Past
30-day
was
self-reported
at
baseline
categorized
into
four
exclusive
patterns:
tobacco-only
use,
cannabis-only
co-use
substances,
non-use.
Anxiety
depression
were
repeatedly
measured
in
monthly
surveys.
To
account
for
multiple
assessments
outcomes
within
participant,
we
used
Generalized
Estimating
Equations
patterns
each
outcome.
Results
In
total
(mean
age
51.0
old,
67.9%
female),
4.9%
reported
6.9%
1.6%
co-use,
86.6%
Proportions
reporting
highest
group
(26.5%
28.3%,
respectively)
lowest
non-use
(10.6%
11.2%,
respectively).
Compared
non-use,
adjusted
odds
(
:
OR
=
1
.
89
,
95%CI
64–2
18;
Depression
77
46–2
16
),
followed
by
use.
(OR
35
08–1
69)
17
00–1
37
)
associated
higher
anxiety,
but
not
Daily
(vs.
non-daily
use)
cigarettes,
e-cigarettes,
Conclusions
Use
cannabis,
particularly
poor
health.
Integrating
support
cessation
may
address
this
co-morbidity.
Frontiers in Pharmacology,
Journal Year:
2023,
Volume and Issue:
14
Published: June 6, 2023
Objective:
Evidence
is
accumulating
that
components
of
the
Cannabis
sativa
plant
may
have
therapeutic
potential
in
treating
psychiatric
disorders.
Medicinal
cannabis
(MC)
products
are
legally
available
for
prescription
Australia,
primarily
through
Therapeutic
Goods
Administration
(TGA)
Special
Access
Scheme
B
(SAS-B).
Here
we
investigated
recent
prescribing
practices
indications
under
SAS-B
by
Australian
doctors.
Methods:
The
dataset,
obtained
from
TGA,
included
information
on
MC
applications
made
doctors
process
between
1st
November
2016
and
30th
September
2022
inclusive.
Details
primary
conditions
treated,
patient
demographics,
prescriber
location,
product
type
(e.g.,
oil,
flower
or
capsule)
general
cannabinoid
content
products.
treated
were
categorized
according
to
Diagnostic
Statistical
Manual
Mental
Disorders,
5th
edition,
text
revision
(DSM-5-TR).
Trends
over
time
analyzed
via
polynomial
regression,
relationships
categorical
variables
determined
correspondence
analyses.
Results:
Approximately
300,000
approvals
prescribe
had
been
issued
period
investigation.
This
38
different
DSM-5-TR
defined
(33.9%
total
approvals).
majority
anxiety
disorders
(66.7%
psychiatry-related
prescribing),
sleep-wake
(18.2%),
trauma-
stressor-related
(5.8%),
neurodevelopmental
(4.4%).
Oil
most
prescribed
(53.0%),
followed
(31.2%)
other
inhaled
(12.4%).
CBD-dominant
comprised
around
20%
particularly
prevalent
treatment
autism
spectrum
disorder.
largest
proportion
was
patients
aged
25-39
years
(46.2%
Recent
dramatic
increases
attention
deficit
hyperactivity
disorder
identified.
Conclusion:
A
significant
Australia
indications.
often
appears
somewhat
"experimental",
given
it
involves
ADHD,
depression)
which
definitive
clinical
evidence
efficacy
lacking.
high
prevalence
THC-containing
being
possible
concern
problems
associated
with
this
drug.
Evidence-based
guidance
use
psychiatry
lacking
would
clearly
be
benefit
prescribers.
Health Promotion and Chronic Disease Prevention in Canada,
Journal Year:
2023,
Volume and Issue:
43(4), P. 182 - 190
Published: Jan. 16, 2023
The
COVID-19
pandemic
has
had
widespread
effects
on
adolescent
mental
health.
However,
little
is
known
about
support-seeking,
unmet
need
and
preferences
for
health
care
among
adolescents.The
Youth
Development
Instrument
(YDI)
a
school-administered
survey
of
adolescents
(N
=
1928,
mean
age
17.1,
SD
0.3)
across
British
Columbia,
Canada.
In
this
cohort,
we
assessed
the
characteristics
accessed
supports,
prevalence
in-person
versus
internet-based
services.Overall,
40%
obtained
support
health,
while
41%
experienced
need.
most
commonly
supports
were
family
doctors
or
pediatricians
(23.1%)
adults
at
school
(20.6%).
preferred
mode
was
counselling
(72.4%),
followed
by
chat-based
services
(15.0%),
phone
call
(8.1%)
video
(4.4%).
adjusted
accessing
elevated
with
anxiety
(adjusted
ratio
[aPR]
1.29,
95%
CI:
1.10-1.51),
those
who
used
alcohol
(1.14,
1.01-1.29),
gender
minorities
(1.28,
1.03-1.58)
sexual
1.03-1.45).
depression
(1.90,
1.67-2.18),
(1.78,
1.56-2.03),
females
(1.43,
1.31-1.58),
(1.45,
1.23-1.70)
(1.15,
1.07-1.23).Adolescents
minority
status
more
likely
than
others
to
have
discussed
concerns
also
reported
common
sources
primary
providers
school,
least
modes
services,
respectively.La
pandémie
de
eu
des
effets
importants
sur
la
santé
mentale
adolescents.
Toutefois,
en
sait
peu
recherche
soutien,
les
besoins
non
comblés
et
préférences
matière
soins
mentale.L’instrument
YDI
(Youth
Instrument,
ou
mesure
du
développement
jeunes)
est
une
enquête
menée
auprès
d’adolescents
1
928;
âge
moyen
17,1;
écart-type
[ET]
0,3)
dans
écoles
Colombie-Britannique
(Canada).
Nous
avons
évalué,
cohorte
l’enquête,
caractéristiques
ressources
soutien
consultées,
prévalence
préférence
pour
offerts
personne
Internet.Dans
l’ensemble,
40
%
ont
déclaré
avoir
consulté
ressource
41
vu
leurs
comblés.
Les
le
plus
souvent
consultées
été
médecins
famille
pédiatres
(23,1
%)
adultes
à
l’école
(20,6
%).
Le
prestation
préféré
par
était
counseling
(72,4
%),
suivi
clavardage
(15,0
téléphone
(8,1
appel
vidéo
(4,4
La
ajustée
l’accès
élevée
chez
souffrant
d’anxiété
(ratio
ajusté
[RPa]
1,29;
intervalle
confiance
[IC]
95
:
1,10
1,51),
consommant
l’alcool
(RPa
1,14;
IC
1,01
1,29),
minorités
genre
1,28;
1,03
1,58)
sexuelles
1,45).
dépression
(1,90;
1,67
2,18),
1,78;
1,56
2,03),
adolescentes
1,43;
1,31
1,58),
(1,45;
1,23
1,70)
1,15;
1,07
1,23).Les
faisant
partie
d’une
minorité
sexuelle
susceptibles
que
autres
d’avoir
parlé
préoccupations
lien
avec
leur
également
fait
état
courantes
fournisseurs
primaires
l’école,
tandis
moins
aimé,
vidéo.Among
adolescents,
during
pandemic,
school.
counselling,
calling.
There
particular
depression,
anxiety,
minorities.
Future
interventions
should
target
these
underserved
groups,
emphasizing
role
care,
school-based
service
options.Chez
pendant
COVID-19,
l’école.
celui
qu’ils
vidéo.
appartenant
nombreux
mentale.
futures
devraient
cibler
ces
groupes
mal
desservis
mettre
l’accent
rôle
primaires,
milieu
scolaire
personne.
The Canadian Journal of Psychiatry,
Journal Year:
2021,
Volume and Issue:
67(4), P. 260 - 268
Published: March 1, 2021
Objective:
With
the
increasing
prevalence
of
cannabis
use,
there
is
a
growing
concern
about
its
association
with
depression
and
suicidality.
The
aim
this
study
was
to
examine
relationship
between
recent
use
suicidal
ideation
using
nationally
representative
data
set.
Methods:
A
cross-sectional
analysis
adults
undertaken
National
Health
Nutrition
Examination
Survey
from
2005
2018.
Participants
were
dichotomized
by
whether
or
not
they
had
used
in
past
30
days.
primary
outcome
ideation,
secondary
outcomes
having
recently
seen
mental
health
professional.
Multiple
logistic
regression
adjust
for
potential
confounders,
survey
sample
weights
considered
model.
Results:
Compared
those
no
(
n
=
18,599),
users
3,127)
more
likely
have
experienced
2
weeks
(adjusted
odds
ratio
[aOR]
1.54,
95%
CI,
1.19
2.00,
P
0.001),
be
depressed
(aOR
1.53,
1.29
1.82,
<
professional
12
months
1.28,
1.04
1.59,
0.023).
Conclusions:
Cannabis
days
associated
thinking
adults.
This
multifactorial
but
highlights
need
specific
guidelines
policies
prescription
medical
psychiatric
therapy.
Future
research
should
continue
characterize
effects
general
population.